Hyloris Pharmaceuticals (XBRU:HYL) Total Liabilities : €8.79 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Total Liabilities?

Hyloris Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was €8.79 Mil.

Hyloris Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2022 (€6.82 Mil) to Jun. 2023 (€8.55 Mil) and increased from Jun. 2023 (€8.55 Mil) to Dec. 2023 (€8.79 Mil).

Hyloris Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 (€15.39 Mil) to Dec. 2022 (€6.82 Mil) but then increased from Dec. 2022 (€6.82 Mil) to Dec. 2023 (€8.79 Mil).

Hyloris Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Hyloris Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Total Liabilities Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

16.17

10.12

15.39

6.82

8.79

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial							15.39	12.38	6.82	8.55	8.79

Hyloris Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hyloris Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.937	+	(1.51	+	0.343
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.79

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	47.612	-	38.822
	=	8.79

Hyloris Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.937	+	(1.51	+	0.343
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.79

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	47.612	-	38.822
	=	8.79

Hyloris Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.